Alterity Therapeutics (Alterity Therapeutics) EV-to-Revenue : (As of Apr. 26, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alterity Therapeutics's enterprise value is $22.14 Mil. Alterity Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Alterity Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Alterity Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Alterity Therapeutics was 1925.81. The lowest was -89.16. And the median was -35.07.

ATHE's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.68
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Alterity Therapeutics's stock price is $2.45. Alterity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Alterity Therapeutics's PS Ratio for today is .

Alterity Therapeutics EV-to-Revenue Historical Data

The historical data trend for Alterity Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics EV-to-Revenue Chart

Alterity Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

Get a 7-Day Free Trial

Alterity Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alterity Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Alterity Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's EV-to-Revenue falls into.

Alterity Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Alterity Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	22.140	/	0
	=

Alterity Therapeutics's current Enterprise Value is $22.14 Mil.
Alterity Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Alterity Therapeutics (NAS:ATHE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Alterity Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.45	/	0
	=

Alterity Therapeutics's share price for today is $2.45.
Alterity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Alterity Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (Alterity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

PBN:Germany ATH:Australia

Address

350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000

Website

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.